To include your compound in the COVID-19 Resource Center, submit it here.

Insulin degludec: Phase III data

An open-label Phase III trial in 459 Type II diabetics showed that a flexible dosing regimen of once-daily insulin

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE